Summary
Johnson & Johnson's (JNJ) 2015 10-K filing for the fiscal year ending December 27, 2014, highlights a diversified healthcare company operating across three key segments: Consumer, Pharmaceutical, and Medical Devices. The company emphasizes its global reach with over 265 operating companies in 60 countries, managed under a decentralized structure. A significant point of discussion is the patent status of its major product, REMICADE®, with key patents set to expire between 2015 and 2018, raising concerns about the potential introduction of biosimilar versions and the impact on future revenues. Despite the patent challenges, JNJ demonstrates a commitment to innovation through substantial Research and Development (R&D) investments, totaling $8.5 billion in 2014. The company also addresses ongoing regulatory matters, including a consent decree related to certain manufacturing operations. Furthermore, JNJ actively managed its capital structure by repurchasing approximately $3.5 billion in common stock during the fourth quarter of 2014 under a new $5.0 billion authorization, signaling confidence in its financial health and commitment to shareholder returns.
Financial Highlights
54 data points| Revenue | $74.33B |
| Cost of Revenue | $22.75B |
| Gross Profit | $51.59B |
| SG&A Expenses | $21.95B |
| Operating Income | $21.59B |
| Interest Expense | $533.00M |
| Net Income | $16.32B |
| EPS (Basic) | $5.80 |
| EPS (Diluted) | $5.70 |
| Shares Outstanding (Basic) | 2.82B |
| Shares Outstanding (Diluted) | 2.86B |
Key Highlights
- 1Johnson & Johnson operates a diversified business across Consumer, Pharmaceutical, and Medical Devices segments, with a significant global presence in 60 countries.
- 2The company is facing patent expirations for its major product REMICADE® between 2015 and 2018, with potential for biosimilar competition, impacting future revenue streams.
- 3Significant investment in Research and Development (R&D) continues, with $8.5 billion spent in fiscal year 2014, underscoring a commitment to innovation and new product pipelines.
- 4Regulatory oversight continues, with specific mention of a consent decree impacting certain Consumer segment manufacturing operations, though remediation efforts were progressing.
- 5The company initiated a $5.0 billion share repurchase program in July 2014 and repurchased approximately $3.5 billion in the fourth quarter, indicating capital return to shareholders.
- 6The divestiture of the Ortho-Clinical Diagnostics business was completed in June 2014, streamlining the Medical Devices segment.